Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Central Nervous System Diseases: early-phase trial registry

7 of 16 indexed Central Nervous System Diseases trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,060 of 28,707 conditions by registered trial count.

16 US clinical trials · 7 currently recruiting · #1,060 of 28,707 conditions by registered trial count

Central Nervous System Diseases: 16 US clinical trials tracked, 7 recruiting.

Central Nervous System Diseases is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Kessler Foundation, running 2 of these trials.

Enrollment posture brief

Registry condition central-nervous-system-diseases

OPEN 7 | RECR 44% | LATE 1 | EARLY 6 | RANK #1060 | SPON 2

Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)

Adolescent62.5%Alcohol Intoxication56.3%Central Nervous System D (th…44%AL Amyloidosis43.8%Allergy18.8%
Open-enrollment share among volume-matched conditions near Central Nervous System Diseases

Central Nervous System Diseases lists 7 open slots (44% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Central Nervous System Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Central Nervous System Diseases is recruiting below its size-band peers.

    7 of 16 indexed trials (43.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Central Nervous System Diseases trials is spread across many organizations.

    Kessler Foundation accounts for 2 of 16 trials (12.5%). 14 distinct sponsors appear on at least one study for this condition label.

  3. Most Central Nervous System Diseases trials plan to enrol fewer than 100 people.

    Median target enrolment is 80 among the 16 trials that report a genuine target (sentinel values excluded). 11 of those (68.8%) plan for fewer than 100 participants.

  4. Central Nervous System Diseases research is mostly interventional.

    15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 31

Open and recent trials

16 total, page 1 of 1

RECRUITING Phase 2 162 participants

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Black Diamond Therapeutics

NCT07326566

RECRUITING NA 76 participants

Brain Connections for Arm Movement After Stroke

VA Office of Research and Development

NCT04286516

RECRUITING Phase 1 73 participants

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Stemline Therapeutics

NCT05386108

RECRUITING Phase 2 21 participants

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

North Florida Foundation for Research and Education

NCT04460872

RECRUITING NA 12 participants

Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)

Kessler Foundation

NCT05731986

RECRUITING NA 10 participants

Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke

Jorge Gonzalez-Martinez

NCT06303869

RECRUITING NA 5 participants

The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)

Kessler Foundation

NCT05725499

ACTIVE NOT RECRUITING NA 20,000 participants

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

Sage Bionetworks

NCT02696603

ACTIVE NOT RECRUITING Phase 3 1,175 participants

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

Eli Lilly and Company

NCT05738486

COMPLETED NA 340 participants

pRESET for Occlusive Stroke Treatment

phenox

NCT03994822

COMPLETED Phase 2 317 participants

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

FORUM Pharmaceuticals

NCT00968851

COMPLETED Phase 2 95 participants

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

Eli Lilly and Company

NCT04640077

COMPLETED Phase 1 80 participants

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

AbbVie (prior sponsor, Abbott)

NCT00649207

COMPLETED NA 80 participants

Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers

Elizabeth K Rhodus

NCT05202223

COMPLETED 21 participants

Central Nervous System Disease in HIV-infected Children on HAART

National Cancer Institute (NCI)

NCT00110331

COMPLETED NA 12 participants

Stimulation With Wire Leads to Restore Cough

MetroHealth Medical Center

NCT01659541

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Central Nervous System Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
Harmony at HOME (H@H) Behavioral
1 trials
donanemab Drug
1 trials
EVP-6124 Drug
1 trials
Whole Brain Radiation Therapy Radiation
1 trials
ABT-888 Drug
1 trials
Mechanical Thrombectomy using the Solitaire Revascularization Device Device
1 trials
Mechanical Thrombectomy using the pRESET Thrombectomy device Device
1 trials

US sites by state

Facility locations filed on Central Nervous System Diseases trials. A trial with sites in several states counts in each.

New Jersey 5 trials
Florida 5 trials
California 5 trials
Pennsylvania 4 trials
Ohio 4 trials
Illinois 4 trials
Texas 3 trials
Maryland 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Central Nervous System Diseases page

16 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 7 Central Nervous System Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Kessler Foundation sponsors the most Central Nervous System Diseases trials on record, review their full trial history before evaluating a specific study. See Kessler Foundation's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Central Nervous System Diseases condition card totals 16 registered trials; most-linked intervention Placebo; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.